We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

QIAGEN Launches First FDA-approved Companion Diagnostic Using FGFR Alterations to Help Guide the Treatment of Metastatic Urothelial Cancer

Product News   Apr 15, 2019

 
QIAGEN Launches First FDA-approved Companion Diagnostic Using FGFR Alterations to Help Guide the Treatment of Metastatic Urothelial Cancer

Image credit: QIAGEN

FURTHER INFORMATION
 
 
Advertisement
 

Related Product News

New Liquid Chromatography-Mass Spectrometry Workstream Offers Comprehensive Solution for Toxicology

Product News

Clinical research, forensic and anti-doping toxicology laboratories facing the challenges of analyzing increasing numbers of analytes in biological matrices, can now easily and rapidly optimize their liquid chromatography-mass spectrometry (LC-MS) methods for targeted screening and quantification.

READ MORE

Canada’s Largest Research Hospital Selects ImmunoGenomiX Platform To Analyze Immune Sequencing Data

Product News

ENPICOM, an innovative bioinformatics software engineering company specialized in decoding the immune system, announced that the Princess Margaret Cancer Centre of the University Health Network (UHN) has purchased a subscription to ENPICOM’s data analysis platform.

READ MORE

Phase III Trial of Janssen's COVID-19 Vaccine Launched

Product News

Johnson & Johnson today announced the launch of its large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) for its COVID-19 vaccine candidate, JNJ-78436735, being developed by its Janssen Pharmaceutical Companies.

READ MORE

Like what you just read? You can find similar content on the communities below.

Biopharma Cancer Research Cell Science Genomics Research

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE